Anthem Biosciences Ltd

AI
Anthem Bioscienc Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Anthem Biosciences Ltd

₹ 937 -0.16%
13 Nov - close price
anthembio.com BSE: 544449 NSE: ANTHEM
About

Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]

Key Points

Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.

Website BSE NSE
  • Market Cap ₹ 52,792 Cr.
  • Current Price ₹ 937
  • High / Low ₹ 989 / 579
  • Stock P/E 79.4
  • Book Value ₹ 60.6
  • Dividend Yield 0.21 %
  • ROCE 32.0 %
  • ROE 24.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 20.4% CAGR over last 5 years
  • Company's working capital requirements have reduced from 113 days to 82.2 days

Cons

  • Stock is trading at 15.5 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology

Part of Nifty LargeMidcap 250 Nifty Midcap 150 Nifty 500 Multicap 50:25:25 BSE Healthcare Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
525 498 479 538 552 417 582 384 572
324 331 281 343 327 254 316 253 307
Operating Profit 201 167 198 195 226 163 267 131 265
OPM % 38% 33% 41% 36% 41% 39% 46% 34% 46%
28 24 38 28 54 15 62 29 65
Interest 3 2 2 2 2 1 2 1 3
Depreciation 19 20 21 23 24 27 26 22 22
Profit before tax 207 170 213 199 253 150 301 136 304
Tax % 18% 25% 42% 25% 22% 25% 30% 25% 27%
170 128 123 148 198 112 212 102 221
EPS in Rs 3.05 2.29 2.19 2.64 3.53 2.00 3.77 1.81 3.92
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
626 633 1,103 1,231 1,057 1,418 1,841 2,089 1,955
454 451 695 666 626 912 1,151 1,238 1,129
Operating Profit 172 182 408 566 431 505 690 851 826
OPM % 27% 29% 37% 46% 41% 36% 37% 41% 42%
21 21 37 49 139 70 109 158 170
Interest 18 20 17 10 9 9 9 7 7
Depreciation 61 62 62 58 64 81 78 100 98
Profit before tax 114 121 366 547 498 485 711 903 891
Tax % 32% 23% 26% 26% 23% 23% 29% 26%
77 93 271 406 386 375 506 671 647
EPS in Rs 1.41 1.70 4.92 7.11 6.76 6.70 9.05 11.94 11.50
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 17%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 26%
TTM: -5%
Compounded Profit Growth
10 Years: %
5 Years: 20%
3 Years: 26%
TTM: 11%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 34%
Return on Equity
10 Years: %
5 Years: 25%
3 Years: 23%
Last Year: 24%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 8 8 8 9 114 112 112 112 113
Reserves 323 413 693 1,347 1,628 1,821 2,361 3,072 3,302
192 159 100 35 115 173 113 50 41
194 207 232 228 136 219 249 296 329
Total Liabilities 718 787 1,034 1,619 1,993 2,324 2,836 3,531 3,784
316 306 361 329 449 478 624 613 598
CWIP 12 50 19 153 143 156 58 84 129
Investments 73 99 209 273 499 472 533 1,380 1,634
318 333 444 865 902 1,219 1,620 1,455 1,423
Total Assets 718 787 1,034 1,619 1,993 2,324 2,836 3,531 3,784

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
196 166 278 333 319 164 300 889
-121 -109 -196 -206 -378 -192 -250 -742
-65 -48 -63 181 53 -132 -68 -44
Net Cash Flow 9 9 18 308 -6 -159 -18 104
Free Cash Flow 144 119 159 308 145 41 171 753
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 114% 116% 85% 81% 101% 56% 67% 128%

Ratios

Standalone / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 68 61 84 97 95 126 89 100
Inventory Days 123 186 29 52 139 129 167 55
Days Payable 72 87 50 58 77 61 54 32
Cash Conversion Cycle 119 160 63 91 157 194 201 122
Working Capital Days 22 20 27 75 114 129 128 82
ROCE % 26% 55% 51% 28% 25% 31% 32%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
CRDMO Revenue Share
%

Log in to view insights

Please log in to see hidden values.

Login
Custom Synthesis Installed Capacity
kL
Fermentation Installed Capacity
kL
Number of Commercial Molecules
count
Number of Late-Phase (Phase 3) Molecules
count
Number of Scientific Staff
count
Custom Synthesis Capacity Utilization
%
Fermentation Capacity Utilization
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
74.69% 74.69% 74.67% 71.42% 71.39%
1.66% 1.37% 1.28% 2.57% 3.79%
7.21% 7.60% 11.55% 13.48% 12.10%
16.42% 16.34% 12.48% 12.52% 12.71%
No. of Shareholders 2,17,6811,99,4921,80,2201,73,2731,76,209

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls